Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
IPO Year:
Exchange: NASDAQ
Website: auriniapharma.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/4/2022 | Outperform → Perform | Oppenheimer | |
5/5/2022 | $34.00 → $25.00 | Overweight | Cantor Fitzgerald |
3/8/2022 | $30.00 → $22.00 | Outperform | SVB Leerink |
3/1/2022 | $31.00 → $27.00 | Outperform | RBC Capital |
2/23/2022 | $34.00 → $31.00 | Outperform | RBC Capital |
12/10/2021 | $33.00 → $31.00 | Perform → Outperform | Oppenheimer |
11/4/2021 | $32.00 → $33.00 | Perform | Oppenheimer |
11/4/2021 | $35.00 → $40.00 | Buy | HC Wainwright & Co. |
11/4/2021 | $28.00 → $35.00 | Outperform | SVB Leerink |
10/28/2021 | $32.00 | Outperform → Perform | Oppenheimer |
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that the Japanese Ministry of Health, Labour, and Welfare has approved voclosporin, a second-generation calcineurin inhibitor, in combination with mycophenolate mofetil (MMF) to treat lupus nephritis (LN). The Company's collaboration partner, Otsuka Pharmaceutical Co., Ltd., filed the new drug application (NDA) with Japanese regulatory authorities in November 2023. The approval is based on data from the AURORA Clinical Program, which included a 12-month, Phase 3, double-blind, randomized-controlled study, as well as a two-year extension study, assessing the efficacy and safety of voclosporin with MMF and lo
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that the Company's management team will attend the 2024 Cantor Fitzgerald Global Healthcare Conference in New York City, September 17-19, 2024. Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat and Q&A session on Tuesday, September 17th, at 3:05 PM EDT. A live webcast of the session will be available on the Investor section of Aurinia's website, which can be found here. About Aurinia Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical n
Peter Greenleaf, President and Chief Executive Officer of Aurinia, remains a Director Kevin Tang, President of Tang Capital Management, LLC, appointed as a Director The Board has accepted the conditional resignations of three directors who received less than majority support at the 2024 Annual General Meeting Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it has restructured its Board of Directors (the Board) to further align the Company with shareholder interests. Peter Greenleaf, President and Chief Executive Officer of Aurinia, remains a Director. Mr. Greenleaf had conditionally resigned as a Director because he received less than majorit
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) announced today that the first participant has been dosed in a Phase 1a single ascending dose (SAD) study of AUR200, a differentiated, potential best-in-class therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The SAD study will assess the safety, tolerability, pharmacokinetics, and changes in biomarkers for AUR200 in healthy volunteers, with data expected in the first half of 2025. "The start of the single ascending dose study is an important milestone for developing AUR200, which has the potential to serve as a best-in-class treatment in autoi
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that the Company's management team will attend the H.C. Wainwright 26th Annual Global Investment Conference in New York City, September 9-11, 2024. Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat and Q&A session on Tuesday, September 10, at 10:30 AM EST. This session will not include a webcast. About Aurinia Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the
Highlights Damning Annual General Meeting Results, Which Show That Four of the Company's Nine Directors Failed to Receive a Majority of the Votes Calls on the Company to Appoint Two Shareholder Representatives to Bring Much-Needed Accountability to the Boardroom Lucien Selce, who owns approximately 2.2% of the outstanding shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) ("Aurinia" or the "Company"), today issued the below open letter to the Board of Directors (the "Board") regarding the urgent need for accountability and boardroom changes. *** August 13, 2024 Aurinia Pharmaceuticals Inc. #140, 14315 – 118 Avenue Edmonton, AB T5L 4S6 Canada Attention: The Board of Directors M
- venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and closing on approximately $528 million in capital commitments in an oversubscribed fundraise. The firm initiated the fundraise for Fund V in mid-April. Limited partners of Fund V include a broad range of institutional investors comprising sovereign wealth funds, corporate pensions, financial institutions, university endowments, medical institutions, foundations, family offices and funds-of-funds. Under the fund leadership of Managing Partners Richard Gaster, M.D., Ph.D., Corey Goo
Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company generated approximately $15.8 million in free cash flow in the second quarter and had cash, cash equivalents, restricted cash and investments of $330.7 million as of June 30, 2024 Company announces development strategy for AUR200, its potential next generation pipeline asset for autoimmune diseases targeting BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand) Company narrows 2024 net product revenue guidance range to $210 to $220 million Confere
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia's management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update. Interested participants can dial (866) 682-6100 or (862) 298-0702 (toll-free U.S. & Canada). The audio webcast can also be accessed here. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to pe
One of Company's Largest and Longest-Standing Shareholders Urges Board to Accept Director Resignations Announces Intentions to Maintain Vigilance and Continue Actions to Restore Shareholder Value ILJIN SNT Co., Ltd. ("ILJIN"), one of the largest shareholders of Aurinia Pharmaceuticals (NASDAQ:AUPH) ("Aurinia" or the "Company"), today issued an open letter to fellow shareholders. The full text of the letter is below. ======================= July 11, 2024 Fellow Aurinia Shareholders, Last month, Aurinia ("Company") announced the voting results of its 2024 annual general meeting of shareholders ("AGM"). The Company announced that four directors -- (i) Peter Greenleaf, President and
Submission status for AURINIA PHARMACEUTICALS, INC.'s drug LUPKYNIS (ORIG-1) with active ingredient VOCLOSPORIN has changed to 'Approval' on 01/22/2021. Application Category: NDA, Application Number: 213716, Application Classification: Type 1 - New Molecular Entity
8-K - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
10-Q - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
8-K - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
8-K - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
DEFA14A - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
ARS - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
DEFA14A - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
DEF 14A - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
10-Q - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
8-K - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced voting results for its 2024 annual general meeting (the Meeting) of shareholders held on June 14, 2024. Shareholders re-elected five of nine incumbent directors to the Board of Directors (the Board). The four directors, while elected under applicable corporate law, who received less than majority support are Peter Greenleaf, Director, President and CEO; Daniel G. Billen, Ph.D., Director, Chair of the Board, Chair of the Compensation Committee, and Member of the Audit Committee; R. Hector MacKay-Dunn, J.D., K.C., Director, Chair of the Governance & Nomination Committee and Member of the Compensation Committ
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) ("Aurinia" or the "Company") today announced that its Board of Directors ("the Board") has appointed Dr. Robert T. Foster to the Board. MKT Capital Ltd. (together with its affiliates, "MKT Capital") submitted Dr. Foster as a candidate and worked collaboratively with Aurinia to name him to the Board. In connection with Dr. Foster's appointment, MKT Capital has entered into a cooperation agreement with Aurinia. A complete copy of the cooperation agreement will be available on our profiles on EDGAR and SEDAR. "We are appreciative of MKT's constructive collaboration efforts. Dr. Foster brings talents which can help strengthen the Board even further
Dr. Karen Smith and Jeffrey A. Bailey joined Aurinia's Board of Directors August 18, 2023 Dr. Daniel G. Billen appointed Chair of the Board of Directors Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) ("Aurinia" or the "Company") today announced that its Board of Directors has appointed two new directors. Dr. Karen Smith and Jeffrey A. Bailey joined the board of directors of the Company effective August 18, 2023, bringing with them decades of combined leadership experience in the pharmaceutical and biotech industry. After conducting a broad search for new directors from a diverse and qualified pool of candidates, Dr. Smith and Mr. Bailey rose to the top because their distinguished careers pr
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) ("Aurinia" or the "Company") today announced voting results for its annual general meeting (the "Meeting") of shareholders held on May 17, 2023. Shareholders re-elected six of eight incumbent directors to the Board of Directors (the "Board"). Two directors, George Milne and Joseph ("Jay") Hagan, while elected under applicable corporate law, received less than majority support and have submitted their resignations for consideration by the Board, pursuant to the Company's Majority Voting Policy. In accordance with the policy, the Board intends to act expeditiously in respect to the submitted resignations to ensure an orderly transition. In additi
Leading independent proxy advisor also recommends shareholders vote for say-on-pay, equity incentive plan amendment, and appointment of auditors Company reminds shareholders to vote today to protect the value of their investment and ensure Aurinia's continued momentum Shareholders with questions or who require assistance voting their shares should contact Laurel Hill Advisory Group toll free within North America at 1-877-452-7184 (1-416-304-0211 outside North America), or by email at [email protected]. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) ("Aurinia" or the "Company") today announced that Glass Lewis & Co. ("Glass Lewis"), a leading independent proxy advisor, has recomme
Volker Knappertz, MD, as Executive Vice President, Research and Development, to lead the consolidated R&D function and to further enhance and advance the Aurinia pipeline Scott Habig, as Chief Commercial Officer, to lead and enhance Aurinia's commercial capabilities, replacing Max Colao, who led the formation of the commercial organization and the launch of Aurinia's first FDA-approved product LUPKYNIS® DeDe Sheel, as Vice President of Investor Relations (IR), to manage all aspects of investor relations programs to support company growth Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the co
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) (Aurinia or the Company) announced today the appointment of Dr. Brinda Balakrishnan, M.D., Ph.D., to the Company's Board of Directors effective June 14, 2021. Dr. Balakrishnan is Group Vice President, Corporate and Business Development of BioMarin Pharmaceutical Inc. ("BioMarin"), a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare disorders. At BioMarin, Dr. Balakrishnan leads initiatives on corporate strategy, mergers and acquisitions, partnering and licensing. This press release features multimedia. View the full release here: https://www.businesswire.c
Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company generated approximately $15.8 million in free cash flow in the second quarter and had cash, cash equivalents, restricted cash and investments of $330.7 million as of June 30, 2024 Company announces development strategy for AUR200, its potential next generation pipeline asset for autoimmune diseases targeting BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand) Company narrows 2024 net product revenue guidance range to $210 to $220 million Confere
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia's management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update. Interested participants can dial (866) 682-6100 or (862) 298-0702 (toll-free U.S. & Canada). The audio webcast can also be accessed here. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to pe
Achieved $50.3 million in total net revenue and $48.1 million in net product revenue for the first quarter of 2024, representing year over year growth of approximately 46% and 40% respectively, and extending the trend of consistent growth in LUPKYNIS® (voclosporin) sales Rapidly completed restructuring while maintaining focus on commercial execution Ahead of prior projections, Company expects to be cash flow positive, excluding share repurchases, in second quarter 2024, with estimated cost savings of $50 to $55 million annually Company reiterates 2024 net product revenue guidance of $200 to $220 million Conference call to be hosted today at 8:30 a.m. ET Aurinia Pharmaceutical
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the first quarter of 2024 on Thursday, May 2, 2024, before markets open. Aurinia's management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update. Interested participants can dial 877-407-9170 / +1 201-493-6756 (Toll-free U.S. & Canada). The audio webcast can also be accessed here. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people liv
Total net revenue was $45.1 million and $175.5 million, and net product revenue was $42.3 million and $158.5 million, for the fourth quarter and full year 2023, respectively $350.7 million of cash, cash equivalents, restricted cash and investments as of December 31, 2023 Reaffirms 2024 net product revenue guidance of $200 - $220 million Announces conclusion of strategic review and details operational changes that are expected to drive savings of approximately $50 - $55 million annually Initiates a share repurchase program of up to $150 million (the maximum amount of which is subject to receipt of regulatory approval in Canada) Conference call to be hosted today at 8:30 a.m.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it will release 2023 fourth quarter and full year financial and operational results on Thursday, February 15, 2024, before markets open. Aurinia's management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update. Interested participants can dial 877-407-9170 / +1 201-493-6756 (Toll-free U.S. & Canada). The audio webcast can also be accessed under "News/Events" through the "Investors" section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia's website. About Aurinia Au
WINNIPEG, Manitoba, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSXV:KNE, OTCQB:KNBIF) (the "Company", "Kane" or "Kane Biotech") announces today that on February 20, 2024, the Company will hold a special meeting of its shareholders (the "Meeting") to consider the election of Dr. Robert Huizinga as an additional director of the Company. The information circular and other materials with respect to the Meeting will be filed on SEDAR+ by the Company in due course. Dr. Huizinga is currently the principal of Reformation Consulting Services. He was formerly the Executive Vice-President of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) and led the clinical development of voclosporin which had
Net product revenue of $40.8 million for the third quarter of 2023; an increase of 60% over the prior year third quarter Total net revenue of $130.4 million for the nine months ended September 30, 2023, an increase of 24% over prior year Achieved European pricing and reimbursement milestone triggering $10 million payment from Otsuka Pharmaceutical Co. Ltd. Narrowing 2023 net product revenue guidance range to $155 - $160 million from net product sales of LUPKYNIS® (voclosporin) Conference call to be hosted today at 8:30 a.m. ET Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today issued its financial results for the three and nine months ended September 30, 202
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the third quarter of 2023, on Thursday, November 2, 2023, before markets open. Aurinia's management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update. Interested participants can dial (888) 645-4404 / (862) 298-0702 (Toll-free U.S. & Canada). The audio webcast can also be accessed under "News/Events" through the "Investors" section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurin
Net revenue increased to $41.5 million for second quarter of 2023; 47% over the prior year second quarter Increases 2023 revenue guidance range to $150 - $160 million from net product sales of LUPKYNIS® (voclosporin) Conference call to be hosted today at 8:30 a.m. ET Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today issued its financial results for the three and six months ended June 30, 2023. Amounts are expressed in U.S. dollars. Total net revenue was $41.5 million for the three months ended June 30, 2023, compared to $28.2 million in the prior year three months ended June 30, 2022, representing growth of approximately 47% year over year. Year to date net r
- Reuters
The Company recommends that shareholders review the recent report from proxy advisor Glass Lewis, which recommends shareholders vote for the re-election to the Board of Directors of all nine incumbent directors.
The data reinforce previous findings on the safety and effectiveness of LUPKYNIS (voclosporin), a second generation calcineurin inhibitor (CNI), in combination with MMF and steroids, for the treatment of adult patients with active lupus nephritis (LN), as shown in the AURORA Clinical Program.
Outlines Concerns Regarding the Company's Current Strategy and Board Composition and Offers Superior Paths to Improving Performance and Market PenetrationLucien Selce, who owns approximately 2.2% of the outstanding shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) ("Aurinia" or the "Company"), today issued the following letter to Aurinia shareholders:May 7, 2024Fellow Shareholders,As a shareholder of Aurinia since 2020, I have grown increasingly worried about the Company's trajectory and am disappointed in the Board of Directors' (the "Board") actions. This is why I now feel dutybound to publicly share my concerns and ideas for improving the Company.In recent years, Aurinia has faced chal
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.14) by 50 percent. The company reported quarterly sales of $50.300 million which beat the analyst consensus estimate of $47.453 million by 6.00 percent. This is a 46.18 percent increase over sales of $34.409 million the same period last year.
SC 13D - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)
SC 13D/A - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)
SC 13G - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)
SC 13G/A - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)
SC 13D/A - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)
SC 13G/A - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)
SC 13G - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)
SC 13D/A - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)
SC 13D/A - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)
SC 13G - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)
Oppenheimer downgraded Aurinia Pharma from Outperform to Perform
Cantor Fitzgerald resumed coverage of Aurinia Pharma with a rating of Overweight and set a new price target of $25.00 from $34.00 previously
SVB Leerink reiterated coverage of Aurinia Pharmaceuticals with a rating of Outperform and set a new price target of $22.00 from $30.00 previously
RBC Capital reiterated coverage of Aurinia Pharmaceuticals with a rating of Outperform and set a new price target of $27.00 from $31.00 previously
RBC Capital reiterated coverage of Aurinia Pharmaceuticals with a rating of Outperform and set a new price target of $31.00 from $34.00 previously
Oppenheimer upgraded Aurinia Pharmaceuticals from Perform to Outperform and set a new price target of $31.00 from $33.00 previously
Oppenheimer reiterated coverage of Aurinia Pharmaceuticals with a rating of Perform and set a new price target of $33.00 from $32.00 previously
HC Wainwright & Co. reiterated coverage of Aurinia Pharmaceuticals with a rating of Buy and set a new price target of $40.00 from $35.00 previously
SVB Leerink reiterated coverage of Aurinia Pharmaceuticals with a rating of Outperform and set a new price target of $35.00 from $28.00 previously
Oppenheimer downgraded Aurinia Pharma from Outperform to Perform and set a new price target of $32.00
3 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)